ClinicalTrials.gg
RecruitingNCT07939698Updated Nov 16, 2026

Individualized Brain Stimulation for Irritable Bowel Syndrome With Depressive Symptoms

An interventional study of Individualized Intermittent Theta-Burst Stimulation and Sham Intermittent Theta-Burst Stimulation in Irritable Bowel Syndrome (IBS) and Depressive Symptoms, sponsored by The Affiliated Hospital of Hangzhou Normal University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by The Affiliated Hospital of Hangzhou Normal University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Dec 2024, registered Nov 2026).
  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 74 studies in Irritable Bowel Syndrome with a site in China — 27 open to participants now, 27 under way, 3 of them phase 3. Irritable Bowel Syndrome · China.

Planned enrollment
45th of 56
60 · median 160
Started
2024
with 9 others
No phase
26 of 74
11 open now
Primary completion
2027-12
later than 20 of 26 live
Registered
74th of 74
by date

Among the 74 studies in Irritable Bowel Syndrome with a site in China, this one is the 45th largest by planned enrollment of the 56 interventional ones that give a count, is one of 10 that started in 2024, is one of 26 with no phase, reaches primary completion later than 20 of the 26 other live ones, and was the 74th registered.

Irritable Bowel Syndrome

1,117 studies on the registry are indexed under Irritable Bowel Syndrome; 209 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

27 of the 74 studies in Irritable Bowel Syndrome with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 127 Irritable Bowel Syndrome studies recruiting now, 33 (26%) set no upper age limit and 84 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Irritable Bowel Syndrome with a site in China, or all of them as a file.
02

Study summary

This randomized, double-blind, sham-controlled trial aims to evaluate the effects of individualized intermittent theta-burst stimulation (iTBS) on depressive and gastrointestinal symptoms in patients with irritable bowel syndrome (IBS) and depressive symptoms.

A total of 60 eligible participants will be randomly assigned in a 1:1 ratio to active or sham stimulation. Individualized stimulation targets within the left dorsolateral prefrontal cortex (DLPFC) will be identified using resting-state functional magnetic resonance imaging (fMRI).

Participants will receive 10 stimulation sessions over two weeks. Clinical assessments and multimodal brain MRI will be performed at baseline and at the end of Week 2. The primary outcome will be the change in depressive symptom severity measured by the 17-item Hamilton Depression Rating Scale (HAMD-17).

An optional ancillary study involving paired stool sample collection at baseline and Week 2 is planned to support future exploratory investigations of gut microbiota and its associations with clinical symptoms and brain network characteristics. This ancillary component will be implemented only after the relevant ethics approval and additional informed consent have been obtained.

03

Conditions studied

  • Irritable Bowel Syndrome (IBS)
  • Depressive Symptoms
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Right-handed individuals.
  • Diagnosis of irritable bowel syndrome according to the Rome IV criteria.
  • Presence of depressive symptoms, defined as a HAMD-17 score greater than 7.
  • Inadequate response to at least two months of conventional treatment for IBS.
  • Ability to understand the study procedures and provide written .
  • Willingness and ability to undergo MRI examinations and complete the study assessments.

Exclusion criteria

Exclusion Criteria:

  • to MRI or transcranial magnetic stimulation.
  • Known food intolerance, relevant gastrointestinal surgery, or gastrointestinal diseases other than IBS that may explain the symptoms.
  • History of significant neurological disorders or psychiatric disorders other than the depressive symptoms under investigation.
  • History of intracranial surgery.
  • Intracranial mass lesions or severe white matter abnormalities detected by MRI.
  • Other conditions that, in the investigator's judgment, would make participation inappropriate or unsafe.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Active Individualized iTBS

    Participants will receive individualized intermittent theta-burst stimulation targeting the left dorsolateral prefrontal cortex. The stimulation target will be identified using resting-state fMRI-guided functional connectivity analysis. Stimulation will be delivered at 90% of the resting motor threshold, with 1,800 pulses per session. Each session will comprise three blocks of 600 pulses, separated by approximately 15-minute intervals. Participants will receive five sessions per week for two weeks, for a total of 10 sessions.

    Device: Individualized Intermittent Theta-Burst Stimulation

  • Sham comparator
    Sham iTBS

    Participants will undergo a sham stimulation procedure with a schedule comparable to the active intervention. The stimulation coil will be positioned at 90 degrees to minimize effective cortical stimulation. Participants will receive five sessions per week for two weeks, for a total of 10 sessions.

    Device: Sham Intermittent Theta-Burst Stimulation

Interventions

  • DeviceIndividualized Intermittent Theta-Burst Stimulation

    Resting-state fMRI-guided iTBS targeting the individualized left dorsolateral prefrontal cortex at 90% of resting motor threshold, delivering 1,800 pulses per session for 10 sessions over two weeks.

  • DeviceSham Intermittent Theta-Burst Stimulation

    A sham stimulation procedure using a coil positioned at 90 degrees, with a treatment schedule comparable to active iTBS.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Depressive Symptom Severity Assessed by HAMD-17 at Week 2

    Depressive symptom severity will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17). A higher score indicates greater depressive symptom severity. The change from baseline to the end of Week 2 will be compared between the active and sham stimulation groups.

    Time frame: Baseline and end of Week 2

Secondary outcomes

  1. Change From Baseline in IBS Symptom Severity at Week 2

    IBS symptom severity will be assessed using the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS). Changes from baseline to the end of Week 2 will be compared between groups.

    Time frame: Baseline and end of Week 2

  2. Change From Baseline in Abdominal Pain Intensity at Week 2

    Abdominal pain intensity will be evaluated using a Visual Analog Scale (VAS).

    Time frame: Baseline and end of Week 2

  3. Change From Baseline in Pain Severity Assessed by the Short-Form McGill Pain Questionnaire at Week 2

    Pain-related symptoms will be assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ).

    Time frame: Baseline and end of Week 2

  4. Change From Baseline in Anxiety Symptom Severity at Week 2

    Anxiety symptom severity will be assessed using the 14-item Hamilton Anxiety Rating Scale (HAMA-14).

    Time frame: Baseline and end of Week 2

  5. Change From Baseline in IBS-Related Quality of Life at Week 2

    IBS-related quality of life will be assessed using the Irritable Bowel Syndrome Quality of Life questionnaire (IBS-QOL).

    Time frame: Baseline and end of Week 2

  6. MRI Outcomes

    functional and structural brain network analyses

    Time frame: Baseline and end of Week 2

  7. Safety Outcomes

    adverse-event incidence

    Time frame: Baseline and end of Week 2

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.

Of 305 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 36 months is above that.

Counting every sponsor, half of 357 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartActual
Dec 1, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939698
Lead sponsor
The Affiliated Hospital of Hangzhou Normal University
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 1, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Jie Li
Contact
jie_sweethz@163.com
+8615988858667

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion